Our scientific publications

MAX BioPharma contributes to the advancement of research worldwide and publishes regularly in scientific journals.

Spine Fusion

NASH

Inflammation

Oncology

Viral Diseases

Bone Repair

Publications

Spine Fusion

Buser Z, Drapeau S, Stappenbeck F, Pereira RC, Parhami F, Wang JC. Effect of Oxy133, an osteogenic oxysterol, on new bone formation in rat two-level posterolateral fusion model. Eur Spine J. 2017 Nov;26(11):2763-2772. doi: 10.1007/s00586-017-5149-9. Epub 2017 May 25. PMID: 28547574.

.

Scott TP, Phan KH, Tian H, Suzuki A, Montgomery SR, Johnson JS, Atti E, Tetratis S, Pereira RC, Wang JC, Daubs MD, Stappenbeck F, Parhami F. Comparison of a novel oxysterol molecule and rhBMP2 fusion rates in a rabbit posterolateral lumbar spine model. Spine J. 2015 Apr 1;15(4):733-42. doi: 10.1016/j.spinee.2014.11.014. Epub 2014 Nov 28. PMID: 25450659; PMCID: PMC4392926.

.

Montgomery SR, Nargizyan T, Meliton V, Nachtergaele S, Rohatgi R, Stappenbeck F, Jung ME, Johnson JS, Aghdasi B, Tian H, Weintraub G, Inoue H, Atti E, Tetradis S, Pereira RC, Hokugo A, Alobaidaan R, Tan Y, Hahn TJ, Wang JC, Parhami F. A novel osteogenic oxysterol compound for therapeutic development to promote bone growth: activation of hedgehog signaling and osteogenesis through smoothened binding. J Bone Miner Res. 2014 Aug;29(8):1872-85. doi:10.1002/jbmr.2213. PMID: 24591126; PMCID: PMC4457783.

.

Johnson JS, Meliton V, Kim WK, Lee KB, Wang JC, Nguyen K, Yoo D, Jung ME, Atti E, Tetradis S, Pereira RC, Magyar C, Nargizyan T, Hahn TJ, Farouz F, Thies S, Parhami F. Novel oxysterols have pro-osteogenic and anti-adipogenic effects in vitro and induce spinal fusion in vivo. J Cell Biochem. 2011 Jun;112(6):1673-84. doi: 10.1002/jcb.23082. PMID: 21503957; PMCID: PMC3080246.

.

Dwyer JR, Sever N, Carlson M, Nelson SF, Beachy PA, Parhami F. Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem. 2007 Mar 23;282(12):8959-68. doi: 10.1074/jbc.M611741200. Epub 2007 Jan 2. PMID: 17200122.

.

Publications

NASH (& Other Fibrotic Conditions)

Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab. 2021 Oct;4(4):e00296. doi: 10.1002/ edm2.296. Epub 2021 Aug 31. PMID: 34505423; PMCID: PMC8502222.

.

Wang F, Stappenbeck F, Parhami F. Oxy210, a Semi-Synthetic Oxysterol, Inhibits Profibrotic Signaling in Cellular Models of Lung and Kidney Fibrosis. Pharmaceuticals (Basel). 2023 Jan 12;16(1):114. doi: 10.3390/ph16010114. PMID: 36678611; PMCID: PMC9862207.

.

Publications

Inflammation

Wang F, Stappenbeck F, Tang LY, Zhang YE, Hui ST, Lusis AJ, Parhami F. Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization. Int J Mol Sci. 2022 May; 23(10): 5478. PMCID: PMC9141227.

.

Publications

Oncology

Stappenbeck F, Wang F, Tang LY, Zhang YE, Parhami F. Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling. Cells. 2019 Oct 22;8(10):1297. doi: 10.3390/cells8101297. PMID: 31652618; PMCID: PMC6829886.

.

Wang F, Stappenbeck F, Parhami F. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties. Cells. 2019 May 27;8(5):509. doi: 10.3390/cells8050509. PMID: 31137846; PMCID: PMC6562610.

.

Wang F, Stappenbeck F, Matsui W, Parhami F. Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol. J Cell Biochem. 2017 Mar;118(3):499-509. doi: 10.1002/jcb.25668. Epub 2016 Sep 21. PMID: 27490478; PMCID: PMC6431790.

.

Tang LY, Spezia M, Chen T, Shin JH, Wang F, Stappenbeck F, Lebensohn AM, Parhami F, Zhang YE. Oxysterol derivatives Oxy186 and Oxy210 inhibit WNT signaling in non-small cell lung cancer. Cell Biosci. 2022 Jul 30;12(1):119. doi: 10.1186/s13578-022-00857-9. PMID: 35908024; PMCID: PMC9338492.

.

Publications

Viral Diseases

Oshima M, Stappenbeck F, Ohashi H, Iwamoto M, Fukano K, Kusunoki A, Zheng X, Wang F, Morishita R, Aizaki H, Suzuki R, Muramatsu M, Kuramochi K, Sureau C, Parhami F, Watashi K. Selective inhibition of hepatitis B virus internalization by oxysterol derivatives. Biochem Biophys Res Commun. 2023 Oct 1;675:139-145. doi: 10.1016/j.bbrc.2023.07.014. Epub 2023 Jul 13. PMID: 37473528.

.

Ohashi H, Wang F, Stappenbeck F, Tsuchimoto K, Kobayashi C, Saso W, Kataoka M, Yamasaki M, Kuramochi K, Muramatsu M, Suzuki T, Sureau C, Takeda M, Wakita T, Parhami F, Watashi K. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro. Int J Mol Sci. 2021 Mar 19;22(6):3163. doi: 10.3390/ijms22063163. PMID: 33808940; PMCID: PMC8003796.

.

Publications

Bone Repair

Li A, Hokugo A, Segovia LA, Yalom A, Rezzadeh K, Zhou S, Zhang Z, Parhami F, Stappenbeck F, Jarrahy R. Oxy133, a novel osteogenic agent, promotes bone regeneration in an intramembranous bone-healing model. J Tissue Eng Regen Med. 2017 May;11(5):1490-1499. doi: 10.1002/term.2047. Epub 2015 Jun 15. PMID: 26073881.

.